Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in PAR?
Paradigm Biopharmaceuticals Ltd: THE INVESTMENT CASE

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions

Paul Rennie talked timeline to clinical trial results with investors.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: PAR The Big Picture
Paul Rennie, chief executive officer, Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, joined Proactive's CEO Sessions in Melbourne on Tuesday 16th May and Sydney on Wednesday 17th May.

Paradigm has results from its Phase 2 hay fever trial pending in six weeks.

ACCESS THE FULL PRESENTATION HERE

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Summit
January 26 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use